{"id":"lng-ee","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The progestin component inhibits the luteinizing hormone (LH) surge necessary for ovulation, while the estrogen suppresses follicle-stimulating hormone (FSH) to prevent follicle development. Together, these hormones also thicken cervical mucus to impede sperm penetration and alter the endometrium to reduce implantation likelihood.","oneSentence":"LNG-EE is a combined oral contraceptive containing levonorgestrel (a progestin) and ethinyl estradiol (an estrogen) that prevents pregnancy by suppressing ovulation and altering cervical mucus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:15.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception / prevention of pregnancy"},{"name":"Regulation of menstrual cycles"}]},"trialDetails":[{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT06942936","phase":"PHASE1","title":"A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-28","conditions":"Healthy Participants","enrollment":51},{"nctId":"NCT07010146","phase":"PHASE2","title":"Role of Estrogen on Skeletal Outcomes in FHA","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-07-01","conditions":"Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)","enrollment":150},{"nctId":"NCT07272889","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":24},{"nctId":"NCT06354257","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-05","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT06028555","phase":"","title":"International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2023-06-28","conditions":"Contraception, Birth Control","enrollment":101000},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT06671405","phase":"PHASE1","title":"An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-25","conditions":"Dyslipidaemia","enrollment":59},{"nctId":"NCT05233956","phase":"NA","title":"Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya","status":"RECRUITING","sponsor":"FHI 360","startDate":"2023-10-23","conditions":"Anemia","enrollment":600},{"nctId":"NCT05896384","phase":"PHASE1","title":"A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-12-21","conditions":"Healthy","enrollment":32},{"nctId":"NCT06793943","phase":"PHASE1","title":"A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-01-23","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT06657105","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-01","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT06783192","phase":"PHASE1","title":"A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-14","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":14},{"nctId":"NCT06380205","phase":"PHASE1","title":"A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-05-07","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT02616146","phase":"PHASE3","title":"Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2015-12-01","conditions":"Contraception","enrollment":2016},{"nctId":"NCT02828904","phase":"","title":"RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2022-03-10","conditions":"Venous Thromboembolism","enrollment":124000},{"nctId":"NCT04778514","phase":"NA","title":"A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention","status":"COMPLETED","sponsor":"Population Council","startDate":"2022-12-07","conditions":"HIV Infections, Contraception","enrollment":30},{"nctId":"NCT05613777","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-11-24","conditions":"Healthy","enrollment":19},{"nctId":"NCT05505162","phase":"PHASE1","title":"Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-08-24","conditions":"Healthy Female Participants","enrollment":24},{"nctId":"NCT00511355","phase":"PHASE3","title":"Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Contraception","enrollment":121},{"nctId":"NCT00511342","phase":"PHASE3","title":"Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Contraception","enrollment":110},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT01873170","phase":"","title":"Quantification of Immune Cells in Women Using Contraception (CHIC II)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-08","conditions":"HIV, Immune Cells (Mucosal and Systemic), Contraception","enrollment":326},{"nctId":"NCT03984825","phase":"PHASE1","title":"Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-06-13","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT04309643","phase":"PHASE1","title":"Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2020-06-09","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT02158572","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2014-08","conditions":"Healthy","enrollment":2032},{"nctId":"NCT03210246","phase":"PHASE1","title":"Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-17","conditions":"Clinical Trial ,Phase I","enrollment":71},{"nctId":"NCT01422135","phase":"PHASE1","title":"Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2011-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT01375946","phase":"PHASE1","title":"Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2011-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT01181479","phase":"PHASE3","title":"Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2010-08","conditions":"Contraception","enrollment":1504},{"nctId":"NCT03478020","phase":"PHASE1","title":"Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2017-11-22","conditions":"Healthy Volunteer","enrollment":32},{"nctId":"NCT01941134","phase":"PHASE4","title":"Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Bariatric Surgery Candidate, Contraception","enrollment":""},{"nctId":"NCT02957630","phase":"PHASE1, PHASE2","title":"\"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\"","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-09","conditions":"Contraception, Liver Metabolism, Hemostasis Parameter","enrollment":101},{"nctId":"NCT01243580","phase":"PHASE1","title":"AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2009-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT01236768","phase":"PHASE3","title":"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2010-10","conditions":"Contraception","enrollment":407},{"nctId":"NCT01963403","phase":"PHASE4","title":"Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2013-12","conditions":"Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy","enrollment":26},{"nctId":"NCT00781456","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2009-01","conditions":"Migraine","enrollment":109},{"nctId":"NCT00196326","phase":"PHASE3","title":"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-06","conditions":"Contraception","enrollment":2235},{"nctId":"NCT00778609","phase":"PHASE3","title":"Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Oral Contraceptive, Headache, Pelvic Pain","enrollment":449},{"nctId":"NCT01170390","phase":"PHASE4","title":"Oral Contraceptives and Body Mass Index","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2009-09","conditions":"Body Weight, Contraceptive Usage","enrollment":32},{"nctId":"NCT02159326","phase":"PHASE1","title":"Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06","conditions":"Drug Interactions","enrollment":31},{"nctId":"NCT02159131","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-08","conditions":"Infections, Human Immunodeficiency Virus and Hepatitis","enrollment":20},{"nctId":"NCT01421368","phase":"PHASE1","title":"Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use","status":"COMPLETED","sponsor":"CONRAD","startDate":"2012-03","conditions":"HIV Prevention","enrollment":72},{"nctId":"NCT01252186","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2010-11","conditions":"Hemostasis, Oral Contraceptive","enrollment":265},{"nctId":"NCT00764881","phase":"PHASE3","title":"Effects of SH T00658ID on Libido","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Contraception, Libido","enrollment":217},{"nctId":"NCT00651846","phase":"PHASE4","title":"Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT00480532","phase":"NA","title":"A Study of Continuous Oral Contraceptives and Doxycycline","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptives, Oral","enrollment":131},{"nctId":"NCT00924560","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2009-06","conditions":"Bone Mineral Density","enrollment":1361},{"nctId":"NCT00117273","phase":"PHASE3","title":"A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT02021097","phase":"PHASE3","title":"Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception","status":"UNKNOWN","sponsor":"Regenex Pharmaceutical, China","startDate":"2012-02","conditions":"Oral Contraceptive","enrollment":1008},{"nctId":"NCT00318799","phase":"PHASE2","title":"Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-04","conditions":"Pregnancy, Unplanned","enrollment":29},{"nctId":"NCT00394771","phase":"PHASE2","title":"A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2006-10","conditions":"Breakthrough Bleeding","enrollment":567},{"nctId":"NCT00996580","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2009-10","conditions":"Pregnancy Prevention","enrollment":3597},{"nctId":"NCT00161681","phase":"PHASE3","title":"Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-07","conditions":"Premenstrual Syndrome","enrollment":200},{"nctId":"NCT01388582","phase":"PHASE4","title":"The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-04","conditions":"Underweight","enrollment":40},{"nctId":"NCT00185367","phase":"PHASE3","title":"Comparative Cycle Control Europe","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-03","conditions":"Contraception","enrollment":798},{"nctId":"NCT00185224","phase":"PHASE2","title":"Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-03","conditions":"Contraception","enrollment":58},{"nctId":"NCT00319163","phase":"PHASE1","title":"Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-05","conditions":"Healthy","enrollment":26},{"nctId":"NCT00128934","phase":"PHASE3","title":"Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-08","conditions":"Menstruation Disturbances, Premenstrual Syndrome","enrollment":744}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 900121"],"phase":"phase_3","status":"active","brandName":"LNG-EE","genericName":"LNG-EE","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LNG-EE is a combined oral contraceptive containing levonorgestrel (a progestin) and ethinyl estradiol (an estrogen) that prevents pregnancy by suppressing ovulation and altering cervical mucus. Used for Contraception / prevention of pregnancy, Regulation of menstrual cycles.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}